We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Innova Biosciences Introduces Range of Conjugated Antibodies

Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Innova Biosciences Introduces Range of Conjugated Antibodies"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Innova Biosciences (Innova) has announced the launch of a range of conjugated antibodies. The unique range leverages Innova’s Lightning-Link® and InnovaCoat® bioconjugation technologies, to provide customers with antibodies conjugated to an extensive range of enzymes, fluorescent dyes and colloidal gold, for improved flexibility in experimental design.

The new range comprises 200 antibodies to nearly 30 different cardiac biomarkers, each available directly conjugated to 24 different enzymes, fluorescent dyes or nanoparticles. Innova intends to expand the range into other key research areas in the near future, catering to an increasingly wide scientific audience.

In conjunction with the new range, Innova has launched a new corporate website, to provide customers with easier online ordering facilities, as well as access to a range of resources and support materials. The website also features an Antibody Conjugate Generator tool, which enables customers ordering from the new conjugated antibodies range to select any desired cardiac marker, antibody clone and label.

The online Conjugate Generator provides Innova’s customers with unprecedented flexibility, speed and conjugation possibilities, enabling highly tailored reagents to be created at a fraction of the cost of a custom conjugation project.

Dr Nick Gee, CEO at Innova, said: "This new range represents a progression for Innova from our range of bioconjugation kits. For the first time we are offering antibodies, capitalizing on our conjugation technologies to create a powerful new tool for researchers.”